Mass Drug Administration of Triclabendazole for Fasciola Hepatica in Bolivia
- 5 June 2019
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 100 (6) , 1494-1497
Abstract
Human infection with Fasciola hepatica leads to obstruction of the common bile duct by adult worms and disease characterized by biliary colic, epigastric pain, and nausea. Recommended treatment is a single dose of triclabendazole (TCBZ) (10 mg/kg). Because in the 1990s the Bolivian Altiplano bordering Lake Titicaca was thought to have the highest prevalence of human fascioliasis worldwide, the Bolivian Ministry of Health instituted TCBZ mass drug administration (MDA). From 2008 to 2016 (excepting 2015), one dose of 250 mg was administered, usually in September/October, to each resident of highly endemic regions willing to participate. This is apparently the first reported use of MDA for Fasciola. The proportion of persons in key regions receiving TCBZ MDA was 87% in 2016. In 2017, we resurveyed key regions, and found that the MDA program had been dramatically successful. Whereas Fasciola prevalence was reported as 26.9% in Huacullani/Tiahuanaco and 12.6% in Batallas in 1999, there was 0.7% prevalence in Huacullani/Tiahuanaco and 1% in Batallas in 2017. However, lessons from schistosomiasis control efforts suggest that for sustained control of Fasciola infection, Fasciola MDA needs to be maintained and coupled with measures to control infection in the intermediary snail and in the animal hosts of F. hepatica.Keywords
This publication has 25 references indexed in Scilit:
- Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infectionCurrent Opinion in Infectious Diseases, 2018
- Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional StudyThe American Journal of Tropical Medicine and Hygiene, 2018
- Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised testInternational Journal for Parasitology: Drugs and Drug Resistance, 2016
- Treatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case SeriesPLOS Neglected Tropical Diseases, 2016
- Evidence of Fasciola spp. resistance to albendazole, triclabendazole and bromofenofos in water buffaloes (Bubalus bubalis).2015
- Fascioliasis and Eosinophilia in the Highlands of Cuzco, Peru and Their Association with Water and Socioeconomic FactorsThe American Journal of Tropical Medicine and Hygiene, 2014
- Can Mass Drug Administration Lead to the Sustainable Control of Schistosomiasis?The Journal of Infectious Diseases, 2014
- Epidemiology of fascioliasis in human endemic areasJournal of Helminthology, 2005
- Fasciola hepatica and lymnaeid snails occurring at very high altitude in South AmericaParasitology, 2001
- A population‐based coprological study of human fascioliasis in a hyperendemic area of the Bolivian AltiplanoTropical Medicine & International Health, 1997